シタデル・エンタープライズ・ジャパン合同会社のプレスリリース（2024年9月2日 09時00分）シタデル、エナジーグリッドの全株式取得を完了

Hedge-fund giant Citadel moved its headquarters to Miami, citing a better corporate environment and concerns over crime in Chicago.

Outpace scientists Chelsea Dunmire (left) and Willimark Obenza examining the results of a lab experiment. (Outpace Photo / Luca Mercedes)Outpace Bio, a Seattle startup using artificial intelligence to design proteins that are incorporated into cancer therapies targeting solid tumors, has raised $144 million in new cash from investors.The fresh funding will allow Outpace researchers to test its treatment in a clinical setting. The goal is to benefit patients and validate the company’s approach to battling cancer.A growing number of cancer treatments harness a type of immune system cell called a T cell to target and destroy cancerous cells. The strategy has been successful for blood cancers, but the solid tumors are better at deflecting the therapies, said Outpace co-founder and CEO Marc Lajoie.So Outpace is modifying the T cells in multiple ways to improve their performance while limiting harmful side effects for patients. “If you think of cancer as a game of Whack-a-Mole, you can’t just whack the first mole and win the game,” Lajoie told GeekWire. “You need to be able to whack each of the moles that comes up